Genomic profiling for targeted treatment in patients with incurable cancer
Proseq Cancer: A Prospective Study of Comprehensive Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
This study is testing if using genetic information from tumors can help find better treatment options for people with incurable cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Aalborg University Hospital Academic / other |
| Locations | 1 site (Aalborg) |
| Trial ID | NCT05695638 on ClinicalTrials.gov |
What this trial studies
Proseq Cancer is a precision medicine program that utilizes whole exome sequencing (WES) and RNA sequencing to identify potential targeted treatments for patients with incurable and progressing cancers. Patients are recruited from the North Denmark Region and undergo clinical-pathological assessments, including biopsies from tumor lesions. The program allows for biobanking and sharing of genomic data while adhering to GDPR regulations. Treatment options may include nationally approved drugs or clinical protocols based on the findings from the National Tumor Board.
Who should consider this trial
Good fit: Ideal candidates are adults with incurable, progressing, and life-threatening cancers who have no efficient remaining standard treatment options.
Not a fit: Patients with a WHO Performance Status greater than 2 or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could provide personalized treatment options for patients with limited standard treatment alternatives.
How similar studies have performed: Other studies utilizing genomic profiling for targeted treatments have shown promise, indicating that this approach is gaining traction in precision medicine.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Incurable, progressing and/or life-threatening cancer * Expected residual survival of at least 3 months * No efficient remaining standard treatment options * Patient recruited from the Region of Northern Jutland, Denmark Exclusion Criteria: * WHO Performance Status \>2 * Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment
Where this trial is running
Aalborg
- Department of Oncology, Aalborg University Hospital — Aalborg, Denmark (Recruiting)
Study contacts
- Principal investigator: Morten Ladekarl, MD, DMSCi — Department of Oncology, Aalborg University Hospital, Denmark
- Study coordinator: Morten Ladekarl, MD, DMSci
- Email: morten.ladekarl@rn.dk
- Phone: +45 97660545
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.